Zacks.com on MSN19h
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
24/7 Wall St. on MSN11h
The Dow Jones Industrials Are Winning 2025: 4 Highest-Yielding Dogs of the Dow Are Steals
With the overall stock market very overbought, the four highest-yielding Dogs of the Dow look like outstanding ideas now.
TMCnet3h
Medidata Advances New Frontiers for Life Sciences Through Patient-Centric Experiences, AI-Powered Innovations, and New Patient Engaging Alliances
A trusted partner to 19 of the top 20 pharmaceutical companies, Medidata continues to break ground with new categories of critical patient-centric experiences, seamlessly integrating AI into its suite ...
The Pharma Letter23h
BRIEF—EC calls for update on regulatory review of lecanemab
Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...
Is Geron A Buyout Target? The RPRX Deal Says No
We argue against selling Geron at current prices, citing strong market potential of imetelstat and Royalty Pharma deal valuation. Read more on GERN stock here.
lifesciencesweden.se23h
Life Science Trends 2025 – Part 4 Neuro
New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver ...